IP Library Granted Patent US 7,569,587
Granted Patent B2
US 7,569,587 · App. 11/652,812 · Granted Aug 4, 2009

Antibacterial mutilins

Assignee: Nabriva Therapeutics AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,587
App. No.
11/652,812
Granted
Aug 4, 2009
Kind
B2
Abstract

A compound of formula (I) wherein R and R 2 and the attached nitrogen atom form pyrrolidinyl or piperidinyl. R 1 is a group of formula (II). R 3 and R′ 3 are hydrogen, deuterium or halogen. R 4 , R 5 and R 10 are independently of each other hydrogen or alkyl. R 6 , R 7 and R 8 are hydrogen or deuterium. R 9 is amino, alkyl, aryl, heterocyclyl or mercapto. If X is oxygen, R 9 is additionally hydrogen; R′ 10 is alkyl, X is sulphur, oxygen, NR 10 , or N+(R′ 10 ) 2 ; Y is sulphur or oxygen, and m is 0,1 or 2, with the proviso that, when R and R 2 and the attached nitrogen atom form piperidinyl, m is O, Y is S and Y is attached in position 3 of the piperidine ring, that group of formula (I) which is attached to the piperidine ring via the residue Y is either in the (S)-configuration or in the (R)-configuration, preferably in the (S)-configuration which is useful as antimicrobial, antibacterial.

Claims (14)

1. A compound of formula I r

wherein

R 3r and R′ 3r are hydrogen, deuterium, or halogen;

R 5r is hydrogen;

R 6r , R 7r and R 8r are hydrogen or deuterium; and

R 1r is that part of an amino acid which remains if the carboxylic group is split off, or a salt thereof.

2. A compound of claim 1 in the form of a salt.

3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a salt thereof and at least one pharmaceutically acceptable carrier or diluent therefor.

4. A pharmaceutical composition of claim 3 , wherein a compound of formula I r

wherein

R 3r and R′ 3r are hydrogen, deuteriurn, or halogen;

R 5r is hydrogen;

R 6r ,R 7r and R 8r are hydrogen or deuterium; and

R 1r is that part of an amino acid which remains if the carboxylic group is split off is in the form of a pharmaceutically acceptable salt.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA AND THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 062881 FRAME: 0090. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
RELEASE OF SECURITY INTEREST Recorded Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
RELEASE OF SECURITY INTEREST Recorded Jan 11, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037455/0436 →
SECURITY INTEREST Recorded Aug 28, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033647/0657 →
CHANGE OF NAME Recorded Aug 11, 2008
From: NABRIVA THERAPEUTICS FORSCHUNGS GMBH
To: NABRIVA THERAPEUTICS AG
Reel/Frame 021371/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2007
From: ASCHER, GERD; BERNER, HEINZ; HILDEBRANDT, JOHANNES
To: NABRIVA THERAPEUTICS FORSCHUNGS GMBH
Reel/Frame 019046/0854 →
Priority Claims (3)
GB 0022439.4 · Sep 13, 2000 · national
GB 0022440.2 · Sep 13, 2000 · national
GB 0024674.4 · Oct 9, 2000 · national
Continuity (2)
Division 1036384000
Related Publication 20070135483A1 · Jun 14, 2007